Danuglipron

Danuglipron
Clinical data
Other names	PF-06882961
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid;
CAS Number	2230198-02-2 ;
PubChem CID	134611040 ;
UNII	DN9IUI24GP ;
ChEBI	CHEBI:231951 ;
ChEMBL	ChEMBL4518483 ;
CompTox Dashboard (EPA)	DTXSID601101457 ;
Chemical and physical data
Formula	C31H30FN5O4
Molar mass	555.610 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1;
	InChI InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1; Key:HYBAKUMPISVZQP-DEOSSOPVSA-N;

Last updated July 18, 2025

Danuglipron is a small-molecule GLP-1 agonist, formerly under development by Pfizer ^[1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.^[2]^[3] However, in April 2025, Pfizer announced it would abandon further development of Danuglipron due to unpredictable liver toxicity.^[4]

References

↑ Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al. (June 2022). "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry. 65 (12): 8208–8226. doi:10.1021/acs.jmedchem.1c01856. PMC 9234956 . PMID 35647711.
↑ Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ (May 2023). "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open. 6 (5): e2314493. doi:10.1001/jamanetworkopen.2023.14493. PMC 10203889 . PMID 37213102.
↑ Constantino AK (2023-12-02). "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops". CNBC. Retrieved 2023-12-03.
↑ Constantino AK (April 14, 2025). "Pfizer scraps daily weight loss pill after liver injury in one patient". CNBC .

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al. (June 2022). "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor". Journal of Medicinal Chemistry. 65 (12): 8208–8226. doi:10.1021/acs.jmedchem.1c01856. PMC 9234956 . PMID 35647711.

[2] Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ (May 2023). "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial". JAMA Network Open. 6 (5): e2314493. doi:10.1001/jamanetworkopen.2023.14493. PMC 10203889 . PMID 37213102.

[3] Constantino AK (2023-12-02). "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops". CNBC. Retrieved 2023-12-03.

[4] Constantino AK (April 14, 2025). "Pfizer scraps daily weight loss pill after liver injury in one patient". CNBC .

[1]

[2]

[3]

[4]

Danuglipron

See also

References